VYNE News and Press, VYNE Therapeutics Inc Com From 04/07/22

VYNE Therapeutics (VYNE +7.3%) announced positive efficacy results from the Phase 1b segment of an early-to-mid stage trial evaluating FMX114 to treat mild-to-moderate atopic dermatitis (AD). The company said at week 2, FMX114 showed statistically significant reduction in both absolute a...

Vyne Therapeutics (NASDAQ:VYNE) has added ~16% in the pre-market Thursday after the clinical-stage biotech announced favorable data from the Phase 1b segment of its Phase 1b/2a clinical trial for the gel product candidate, FMX114, targeted at mild-to-moderate atopic dermatitis (...

At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehicle Phase 2a safety and efficacy results expected in the second quarter BRIDGEWATER, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- VYNE The...

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses VYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable steroid, dexamethasone, in inhibi...

VYNE Therapeutics press release (NASDAQ:VYNE): Q4 Non-GAAP EPS of -$0.20 beats by $0.06. Revenue of $2.29M (-46.6% Y/Y) misses by $1.83M. CEO comment: “We have several important milestones slated throughout the remainder of 2022 for our three novel immuno-inflammatory pipeline programs...

FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and validated inflammation models BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasd...

VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin disorder. VYN201 0.1% and 1% demonstrated upregulaton of the WNT signalling pathway,...

BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions...

Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean C max of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared to the lowe...

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE...